10x Genomics, Inc. is trading 3.3% up now at $30.57, extending a multi-day rebound after a recent earnings report showed better-than-expected Q1 CY2026 revenue.
- Investors appear to be reassessing the stock following the upside revenue surprise, even though total sales declined on a year-over-year basis.
- Shares are materially outperforming broader market indices, supported by ongoing momentum within the life sciences tools sector.